StreetInsider.com News Articles

Form DEF 14C Sunshine Biopharma Inc. For: Mar 02

Mon, 02 Mar 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260302/26091929.html

Form DEF 14C Sunshine Biopharma Inc. For: Mar 02

Mon, 02 Mar 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260302/26091929.html

Form 8-K Sunshine Biopharma Inc. For: Feb 18

Fri, 20 Feb 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260220/26036084.html

Form 8-K Sunshine Biopharma Inc. For: Feb 18

Fri, 20 Feb 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260220/26036084.html

Form PRE 14C Sunshine Biopharma Inc. For: Feb 18

Fri, 20 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260220/26035978.html

Form PRE 14C Sunshine Biopharma Inc. For: Feb 18

Fri, 20 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260220/26035978.html

Form 8-K Sunshine Biopharma Inc. For: Feb 05

Thu, 05 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260205/25955112.html

Form 8-K Sunshine Biopharma Inc. For: Feb 05

Thu, 05 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260205/25955112.html

Form 8-K Sunshine Biopharma Inc. For: Dec 11

Fri, 12 Dec 2025 16:05:00 -0500

si-local-file:///var/storage/secattach/20251212/25734523.html

Sunshine Biopharma Inc. (SBFM) PT Lowered to $6 at Aegis Capital

Tue, 18 Nov 2025 05:23:29 -0500

Aegis Capital analyst David Bouchey lowered the price target on Sunshine Biopharma Inc. (NASDAQ: SBFM) to $6.00 (from $7.00) while maintaining a Buy rating.

Form 10-Q Sunshine Biopharma Inc. For: Sep 30

Thu, 13 Nov 2025 16:09:00 -0500

si-local-file:///var/storage/secattach/20251113/25607311.html

Sunshine Biopharma receives Health Canada approval for domperidone marketing

Tue, 28 Oct 2025 14:10:52 -0500

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced it received authorization from Health Canada to commercialize domperidone through its Nora Pharma subsidiary.

The company stated that global domperidone sales are projected to reach $1.36 billion by the end of 2025, with North America accounting for approximately 39% of that market. Canada represents nearly 17% of the North American share, according to the press release.

Trading volume in SBFM stock increased more than 1600% to nearly 10 million shares following the announcement, the company reported.

Sunshine Biopharma currently markets 72 generic prescription drugs in Canada and plans to launch more than 12 additional drugs in the

Sunshine Biopharma receives Health Canada approval for domperidone marketing

Tue, 28 Oct 2025 14:10:52 -0500

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced it received authorization from Health Canada to commercialize domperidone through its Nora Pharma subsidiary.

Trading volume in SBFM stock increased more than 1600% to nearly 10 million shares following the announcement, the company reported.

Sunshine Biopharma currently markets 72 generic prescription drugs in Canada and plans to launch more than 12 additional drugs in the

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Tue, 28 Oct 2025 14:10:00 -0500

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ:SBFM) is quickly establishing which side of that line it's on. After scoring another major regulatory win, that position certainly isn't one of many in the crowd. On Tuesday, the company announced that it had secured Health Canada authorization to commercialize domperidone through its Nora Pharma subsidiary, a milestone that not only expands its commercial reach but also validates its growing track record of

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Tue, 28 Oct 2025 14:10:00 -0500

Sunshine Biopharma receives Health Canada approval for domperidone

Tue, 28 Oct 2025 07:45:47 -0500

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced that its subsidiary Nora Pharma Inc. received approval from Health Canada to commercialize domperidone, a prescription medication used to treat nausea and vomiting while enhancing gastrointestinal motility.

The medication is used for chemotherapy-induced nausea and vomiting, particularly for patients who cannot tolerate other antiemetics that may cause extrapyramidal side effects. Domperidone functions by blocking dopamine receptors in the gut to reduce nausea and improve gastric motility.

According to Cognitive Market Research data cited in the company's announcement, global domperidone sales are projected to reach $1.36 billion by the end of 2025. North America represents approximately 39%

Sunshine Biopharma receives Health Canada approval for domperidone

Tue, 28 Oct 2025 07:45:47 -0500

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Tue, 28 Oct 2025 07:45:00 -0500

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced that its wholly owned subsidiary, Nora Pharma Inc., has received approval from Health Canada, the Canadian equivalent to the FDA, for the commercialization of Domperidone, a prescription medication used to relieve nausea and vomiting and to enhance gastrointestinal motility.

Domperidone is often used for chemotherapy-induced nausea and vomiting, especially when patients cannot tolerate other antiemetics which may cause extrapyramidal side effects. Domperidone works

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Tue, 28 Oct 2025 07:45:00 -0500

Domperidone is often used for chemotherapy-induced nausea and vomiting, especially when patients cannot tolerate other antiemetics which may cause extrapyramidal side effects. Domperidone works

Form DEFA14A Sunshine Biopharma Inc.

Thu, 23 Oct 2025 16:57:00 -0500

si-local-file:///var/storage/secattach/20251023/25495805.html

Form DEF 14A Sunshine Biopharma Inc. For: Dec 11

Thu, 23 Oct 2025 16:56:00 -0500

si-local-file:///var/storage/secattach/20251023/25495802.html

Sunshine Biopharma launches generic doxycycline in Canada

Mon, 20 Oct 2025 07:45:33 -0500

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced the commercial launch of generic doxycycline in Canada. The antibiotic is now available to pharmacies, hospitals and healthcare providers nationwide.

Doxycycline treats respiratory tract infections, urinary tract infections, sexually transmitted diseases, acne, and tick-borne illnesses including Lyme disease. The company's version comes in 100 mg tablets and is manufactured in compliance with Health Canada's regulatory framework.

"Launching Doxycycline in Canada aligns with our mission to deliver high-quality, affordable medications that meet real clinical needs," said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

The global doxycycline market was valued at approximately $729 million in 2024 and is projected

Sunshine Biopharma launches generic doxycycline in Canada

Mon, 20 Oct 2025 07:45:33 -0500

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced the commercial launch of generic doxycycline in Canada. The antibiotic is now available to pharmacies, hospitals and healthcare providers nationwide.

"Launching Doxycycline in Canada aligns with our mission to deliver high-quality, affordable medications that meet real clinical needs," said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

The global doxycycline market was valued at approximately $729 million in 2024 and is projected

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Mon, 20 Oct 2025 07:45:00 -0500

FORT LAUDERDALE, FL, QC / ACCESS Newswire / October 20, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced the commercial launch of generic Doxycycline in Canada. This strategic move strengthens the Company's footprint in the Canadian growing antibiotic sector. Doxycycline is now available to pharmacies, hospitals and healthcare providers nationwide.

Doxycycline is a broad-spectrum antibiotic used to treat respiratory tract infections, urinary tract infections, sexually transmitted diseases, acne, and tick-borne illnesses such as Lyme disease. With high oral bioavailability and

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Mon, 20 Oct 2025 07:45:00 -0500